Larimar Therapeutics, Inc. (LRMR) |
| 4.8 0.08 (1.69%) 04-17 16:00 |
| Open: | 4.81 |
| High: | 4.87 |
| Low: | 4.71 |
| Volume: | 896,925 |
| Market Cap: | 411(M) |
| PE Ratio: | -2.11 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 6.25 |
| Resistance 1: | 5.35 |
| Pivot price: | 4.81 |
| Support 1: | 4.64 |
| Support 2: | 4.20 |
| 52w High: | 6.42 |
| 52w Low: | 1.73 |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Financials
| EPS | -2.270 |
| Book Value | 0.940 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -62.3 |
| Return on Equity (ttm) | -132.6 |
Company news
Tue, 14 Apr 2026
LRMR Forecast, Price Target & Analyst Ratings | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR) - ChartMill
Fri, 10 Apr 2026
Larimar Therapeutics (NASDAQ: LRMR) asks shareholders to double authorized shares to 215M - Stock Titan
Fri, 27 Mar 2026
Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13 - Yahoo Finance
Thu, 19 Mar 2026
FDA grants Breakthrough status to rare disease drug as June filing nears - Stock Titan
Mon, 09 Mar 2026
Larimar Therapeutics posts updated corporate deck outlining nomlabofusp BLA plan, Q2 2026 topline and cash runway - TradingView — Track All Markets
Sat, 28 Feb 2026
Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed? - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
